Communication and Cooperation

Communication and Cooperation

Communication and Cooperation

The Group has always attached great importance to the cooperation and exchanges with domestic and international scientific research organizations, and we closely follow the development trend of advanced technologies. The Group maintains close partnerships with various organizations.

Shanghai Institute of Materia Medical

Shanghai Institute of Materia Medical

JV established: Shanghai Runshi Pharma Technology Co.

Co-developing 4 small molecule new drug candidates

NonWith Simmitinib and 3 other products entering clinical trial stage

Shanghai Institute of Materia Medical

Shanghai Institute of Materia Medical

Columbia University Drug discovery joint lab

SYHA1 402 commenced clinical trial

Tianjin University

Tianjin University

CADD joint lab

Early-stage screening platform for small

molecules
SYHA121-28 is about to enter into pivotal clinical trial

Tianjin University

Tianjin University

Established AlaMab

Co-op on first-in-class target discovery and antibody development

ALMB0166 & ALMB0168 have started clinical trials

Sichuan University

Sichuan University

Formed strategic partnership

SKLB1028 entering pivotal clinical trial stage

Teva Pharmaceutical

Teva Pharmaceutical

Co-development on multiple new preparations

lrinotecan liposome filed in China and the U.S.simultaneously; will apply for marketingregistration soon in China

Amphotericin B liposome applied in China and the U.S. simultaneously

Communication and Cooperation

The Group actively seeks various cooperation opportunities and looks for acquisition targets with strong R&D capabilities in the biopharmaceutical field to further

supplement the pipeline of products under development. Future cooperation objectives will be mainly large and small molecule new drugs that are about to be approved for marketing, which will enrich the new drug list that are potentially to be launched in the next few years. Relying on the Group's strong R&D capabilities, the number of new products will see a rapid increase in the next few years. At the same time, our R&D team has been working on seeking new cooperation opportunities with global scientific research institutions and technology companies.

Communication and Cooperation

Entered into a strategic partnership and license agreement with Flame Biosciences, Inc., a U.S. innovative pharmaceutical company, to out-license the exclusive rights outside of Greater China of the Group’s drug candidate NBL-015 (an anti-Claudin 18.2 monoclonal antibody) and two new bispecific antibodies to be developed based on the Group’s NovaTE bispecific antibody technology platform.

Communication and Cooperation

Entered into a collaboration with Beta Pharma (Shanghai) Company Limited to obtain the exclusive product license and commercialization rights of rezetinib mesylate capsules (BPI-7711) (a third generation irreversible EGFR-TKI for the treatment of non-small cell lung cancer) in China.

Communication and Cooperation

Entered into a collaboration with Keymed Bioscience (Chengdu) Co., Ltd. (“Chengdu Keymed”) to obtain the exclusive product license and commercialization rights of CM310 (an anti-IL-4Rα recombinant humanized monoclonal antibody) for moderate to severe asthma and chronic obstructive pulmonary disease (COPD) in China.


Entered into a collaboration with Chengdu Keymed to obtain the exclusive product license and commercialization of CM326 (an anti-TSPL recombinant humanized monoclonal antibody) for moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory system diseases in China.

Entered into a strategic alliance agreement with Chengdu Keymed to cooperate on the clinical development and commercialization of a variety of nervous system disease products.

Communication and Cooperation

Entered into a collaboration with Jiangsu Alphamab Oncology Co., Ltd. to obtain the exclusive product license and commercialization rights of KN026 (a HER2-targeted bispecific antibody) for breast cancer and gastric cancer in China.

Communication and Cooperation

Acquired 51% equity interest in Guangzhou Recomgen Biotech Co., Ltd. (“Recomgen Biotech”) in February 2022. Mingfule (銘復樂) (recombinant human TNK tissue-type plasminogen activator for injection), a marketed product of Recomgen Biotech, is a third-generation specific thrombolytic drug with intellectual property rights for the treatment of thrombolysis in patients with acute myocardial infarction within 6 hours of onset. The product is currently undergoing Phase III trial (TRACE II) for the indication of thrombolysis in cerebral infarction, with a huge potential market.

Communication and Cooperation

Entered into an exclusive license agreement with Elevation Oncology, Inc. (“Elevation Oncology”) for the development and commercialization of the Group’s SYSA1801, a novel (first-in-class) anti-Claudin 18.2 antibody-drug conjugate (ADC) (the “Product”) outside of Greater China (including mainland China, Hong Kong, Macau and Taiwan).

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat